| Abstrakt: |
A recent study conducted in Fujian, People's Republic of China, focused on the development of a vaccine for viral myocarditis (VMC) caused by the Coxsackie B3 virus (CVB3). The researchers prepared chitosan (chi)-C-terminal 30 amino acid (CPE30) particles and formed chi-CPE30-pcDNA3.1-VP1 plasmid (pVP) complex particles. These particles were then used to immunize rats, and the results showed that the vaccine induced high levels of antibodies and a proliferative response of CVB-specific lymphocytes. The study suggests that this vaccine could be a new approach for preventing and treating CVB3 infection. [Extracted from the article] |
